{"id":"https://openalex.org/W2809596334","doi":"https://doi.org/10.1093/neuonc/noy059.610","title":"QOL-28. CUTANEOUS REACTIONS TO TARGETED THERAPIES IN CHILDREN WITH CNS TUMORS: A CROSS-SECTIONAL STUDY","display_name":"QOL-28. CUTANEOUS REACTIONS TO TARGETED THERAPIES IN CHILDREN WITH CNS TUMORS: A CROSS-SECTIONAL STUDY","publication_year":2018,"publication_date":"2018-06-01","ids":{"openalex":"https://openalex.org/W2809596334","doi":"https://doi.org/10.1093/neuonc/noy059.610","mag":"2809596334"},"language":"en","primary_location":{"id":"doi:10.1093/neuonc/noy059.610","doi":"https://doi.org/10.1093/neuonc/noy059.610","is_oa":false,"landing_page_url":"https://doi.org/10.1093/neuonc/noy059.610","pdf_url":null,"source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6012680","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065520106","display_name":"Connie S. Zhong","orcid":"https://orcid.org/0000-0003-1222-360X","observed_orcids":["https://orcid.org/0000-0003-1222-360X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Connie Zhong","raw_affiliation_strings":["Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049661758","display_name":"Hannah Song","orcid":"https://orcid.org/0000-0002-9999-4943","observed_orcids":["https://orcid.org/0000-0002-9999-4943"]},"institutions":[{"id":"https://openalex.org/I1288882113","display_name":"Boston Children's Hospital","ror":"https://ror.org/00dvg7y05","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hannah Song","raw_affiliation_strings":["Boston Children\u2019s Hospital, Boston, MA, USA","Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston Children\u2019s Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1288882113"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060208068","display_name":"Mark W. Kieran","orcid":"https://orcid.org/0000-0003-2184-7692","observed_orcids":["https://orcid.org/0000-0003-2184-7692"]},"institutions":[{"id":"https://openalex.org/I4210166317","display_name":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center","ror":"https://ror.org/05k11pb55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113","https://openalex.org/I4210117453","https://openalex.org/I4210166317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Kieran","raw_affiliation_strings":["Dana-Farber/Boston Children\u2019s Cancer Center and Blood Disorder Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber/Boston Children\u2019s Cancer Center and Blood Disorder Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210166317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068793931","display_name":"Susan N Chi","orcid":"https://orcid.org/0000-0001-7753-878X","observed_orcids":["https://orcid.org/0000-0001-7753-878X"]},"institutions":[{"id":"https://openalex.org/I4210166317","display_name":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center","ror":"https://ror.org/05k11pb55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113","https://openalex.org/I4210117453","https://openalex.org/I4210166317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Chi","raw_affiliation_strings":["Dana-Farber/Boston Children\u2019s Cancer Center and Blood Disorder Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber/Boston Children\u2019s Cancer Center and Blood Disorder Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210166317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090423495","display_name":"Karen D. Wright","orcid":"https://orcid.org/0000-0002-9578-1545","observed_orcids":["https://orcid.org/0000-0002-9578-1545"]},"institutions":[{"id":"https://openalex.org/I4210166317","display_name":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center","ror":"https://ror.org/05k11pb55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113","https://openalex.org/I4210117453","https://openalex.org/I4210166317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Wright","raw_affiliation_strings":["Dana-Farber/Boston Children\u2019s Cancer Center and Blood Disorder Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber/Boston Children\u2019s Cancer Center and Blood Disorder Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210166317"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003107485","display_name":"Jennifer T. Huang","orcid":"https://orcid.org/0000-0001-6191-7486","observed_orcids":["https://orcid.org/0000-0001-6191-7486"]},"institutions":[{"id":"https://openalex.org/I1288882113","display_name":"Boston Children's Hospital","ror":"https://ror.org/00dvg7y05","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Huang","raw_affiliation_strings":["Boston Children\u2019s Hospital, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston Children\u2019s Hospital, Boston, MA, USA","institution_ids":["https://openalex.org/I1288882113"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5132,"currency":"USD","value_usd":5132},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"20","issue":"suppl_2","first_page":"i163","last_page":"i163"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-induced-skin-reaction","display_name":"drug-induced skin reaction","score":0.8610000014305115},{"id":"https://openalex.org/keywords/pediatric-brain-tumors","display_name":"pediatric brain tumors","score":0.8270000219345093},{"id":"https://openalex.org/keywords/braf-v600e-inhibitors","display_name":"BRAF V600E inhibitors","score":0.902999997138977},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.9520000219345093},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9369999766349792},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":1.0},{"id":"https://openalex.org/keywords/hand-foot-syndrome","display_name":"hand-foot syndrome","score":0.9179999828338623},{"id":"https://openalex.org/keywords/dry-skin","display_name":"dry skin","score":0.972000002861023},{"id":"https://openalex.org/keywords/paronychia","display_name":"paronychia","score":0.968999981880188},{"id":"https://openalex.org/keywords/alopecia","display_name":"hair loss","score":0.9710000157356262},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6000000238418579},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.867937445640564},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.6315097212791443},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.5786820650100708},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5547338128089905},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4900892972946167},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46162205934524536},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.45921680331230164},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4416777193546295},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44016724824905396},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3696814477443695},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.3663274049758911},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.15337732434272766},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.09232690930366516},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/neuonc/noy059.610","doi":"https://doi.org/10.1093/neuonc/noy059.610","is_oa":false,"landing_page_url":"https://doi.org/10.1093/neuonc/noy059.610","pdf_url":null,"source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6012680","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6012680","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro Oncol","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:6012680","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6012680","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro Oncol","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2919781000","https://openalex.org/W3043280112","https://openalex.org/W2763890667","https://openalex.org/W2566164067","https://openalex.org/W4398228956","https://openalex.org/W3115543520","https://openalex.org/W4281759277","https://openalex.org/W4387014984","https://openalex.org/W4384563150","https://openalex.org/W4281745660"],"abstract_inverted_index":{"The":[0,45,225],"MAPK":[1],"and":[2,13,23,56,70,114,157,176,192,202,246],"mTOR":[3,14,71,91,117,183],"pathways":[4,22],"play":[5],"important":[6],"roles":[7],"in":[8,27,41,61],"cell":[9],"proliferation.":[10],"BRAF,":[11,68],"MEK,":[12,69],"inhibitors":[15,92,145,165,184,201],"are":[16,24,38,43],"novel":[17],"therapies":[18],"that":[19,228],"inhibit":[20],"these":[21],"increasingly":[25],"utilized":[26],"the":[28,54,143,163,182,199,206],"pediatric":[29],"population":[30],"with":[31,63,67,81],"CNS":[32,82],"tumors.":[33],"While":[34],"associated":[35],"cutaneous":[36,59,215,229],"reactions":[37,60,148,168,186,230,243],"common,":[39],"data":[40],"children":[42,62],"sparse.":[44],"objective":[46],"of":[47,58,79,132],"this":[48],"cross-sectional":[49],"study":[50,122,221,226],"was":[51,124,218],"to":[52,213],"investigate":[53],"frequency":[55],"type":[57],"brain":[64],"tumors":[65,83],"treated":[66],"inhibitor":[72,208],"monotherapy.":[73],"Patients":[74],"less":[75],"than":[76],"21":[77],"years":[78,126],"age":[80,120],"on":[84,106,110,116,142,162,181,198,205],"BRAF":[85,111,164,207],"V600E":[86,112],"(dabrafenib),":[87],"MEK":[88,107,144,200],"(trametinib),":[89],"or":[90],"(everolimus)":[93],"were":[94,102,149,231,244],"enrolled":[95],"over":[96],"a":[97,239],"one-year":[98],"period.":[99],"Twenty-two":[100],"patients":[101,133,141,161,180,197],"enrolled,":[103],"including":[104],"11":[105],"inhibitors,":[108,113],"6":[109],"5":[115],"inhibitors.":[118],"Median":[119],"at":[121,135],"visit":[123],"12":[125],"(3-19":[127],"yrs).":[128],"Ninety-six":[129],"percent":[130],"(21/22)":[131],"had":[134],"least":[136],"one":[137,203],"skin":[138],"finding.":[139],"In":[140,160,179],"(11),":[146],"common":[147,167,233],"follicular":[150,170,193],"eruptions":[151,171],"(9),":[152],"xerosis":[153,177,188],"(8),":[154],"paronychia":[155,190],"(4),":[156,189],"alopecia":[158],"(2).":[159],"(6),":[166,172],"included":[169,187],"hand-foot":[173],"syndrome":[174],"(5),":[175,185],"(3).":[178],"(1),":[191],"eruption":[194],"(1).":[195],"Two":[196],"patient":[204],"required":[209,247],"therapy":[210,248],"cessation":[211],"due":[212],"severe":[214,245],"reactions.":[216],"Treatment":[217],"recommended":[219],"for":[220,238],"participants":[222],"as":[223],"indicated.":[224],"demonstrates":[227],"extremely":[232],"but":[234],"generally":[235],"well-tolerated,":[236],"though":[237],"small":[240],"subset,":[241],"their":[242],"cessation.":[249]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-06-29T00:00:00"}